The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.

The aim of this study was to ascertain the potential usefulness of the antiangiogenic compound linomide for treatment of von Hippel-Lindau (VHL)-related tumors. Paraganglioma tissue fragments obtained at surgery from a VHL type 2a patient were transplanted s.c. to male BALB/c nu/nu (nude) mice: (a) 2-3-mm fragments for "prevention" experiments; and (b) 2-3-mm fragments allowed to grow to 1 cm for "intervention" studies. Both groups received either 0.5 mg/ml linomide in drinking water or acidified water and were followed until tumor diameter reached 3 cm or for 4 weeks. In both the prevention and intervention experiments, a significant diminution of tumor size and weight was observed in the drug-treated animals. In vivo nuclear magnetic resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels almost exclusively to the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and vasodilation. Histological examination of tumors from linomide-treated animals revealed marked avascularity. Treated animals also displayed a 2.4-fold reduction of tumor vascular endothelial growth factor mRNA levels. Taken together, our data indicate that in VHL disease, therapy directed at inhibition of constitutively expressed VEGF induction of angiogenesis by VHL tumors may constitute an effective medical treatment.

[1]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[2]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Isaacs,et al.  Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers , 1995, The Prostate.

[4]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[5]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[6]  B. Zbar,et al.  Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. , 1996, The Journal of clinical endocrinology and metabolism.

[7]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[8]  A. Passaniti,et al.  Antiangiogenic effects of the quinoline-3-carboxamide linomide. , 1993, Cancer research.

[9]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[10]  A. V. van Oosterom,et al.  An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. , 1997, European journal of cancer.

[11]  W. Linehan,et al.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.

[12]  J. Isaacs,et al.  Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. , 1995, Cancer research.

[13]  R. Paridaens,et al.  EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. , 1997, European journal of cancer.

[14]  J. Isaacs,et al.  The antiangiogenic agent linomide inhibits tumor necrosis factor‐α secretion via inhibition of its synthesis , 1996, The Prostate.

[15]  Morris Pollard.  Effects of linomide on advanced prostate‐seminal vesicle cancers in Lobund‐Wistar rats , 1998, The Prostate.

[16]  H. Granger,et al.  The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor , 1996, British journal of pharmacology.

[17]  J. Isaacs,et al.  Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. , 1997, Cancer research.

[18]  J. Isaacs,et al.  The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. , 1992, Cancer research.

[19]  K. Plate,et al.  Pathology, genetics and cell biology of hemangioblastomas. , 1996, Histology and histopathology.

[20]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[21]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[22]  S. Donnini,et al.  Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. , 1998, British Journal of Cancer.

[23]  A. Nagler,et al.  Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide. , 1998, Connective tissue research.

[24]  J. Isaacs,et al.  Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. , 1996, Cancer research.

[25]  W. Linehan,et al.  Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. , 1997, Human pathology.

[26]  J. Isaacs,et al.  Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. , 1995, Cancer research.

[27]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[28]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[29]  M. Goldberg,et al.  Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.

[30]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.

[31]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[32]  M. Neeman,et al.  Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging , 1998, Magnetic resonance in medicine.

[33]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.